舒利迭联合标准桃金娘油肠溶胶囊治疗慢性阻塞性肺疾病的疗效及对血清SIRT1 sfrp5 MRpro-ADM的影响
|
摘要
目的:探讨舒利迭联合标准桃金娘油肠溶胶囊治疗慢性阻塞性肺疾病的疗效及对血清沉默信息调节因子2相关酶(SIRT1)、分泌型卷曲相关蛋白5(sfrp5)、肾上腺髓质素前体中段肽(MRpro-ADM)的影响。方法:选择2016年4月至2018年4月我院接诊的100例慢性阻塞性肺疾病患者进行研究,通过简单随机数表法分为观察组55例和对照组45例,在常规治疗基础上,对照组给予舒利迭治疗,观察组在对照组基础上联合标准桃金娘油肠溶胶囊治疗,均连续治疗8周。比较两组临床疗效、血清SIRT1、sfrp5、MRpro-ADM、肺功能、英国医学研究委员会呼吸问卷(mMRC)评分及不良反应。结果:治疗后,观察组临床疗效总有效率明显高于对照组(P<0.05);观察组血清SIRT1、sfrp5明显高于对照组,MRpro-ADM明显比对照组低(P<0.05);观察组第1秒用力呼气容积(FEV1)、FEV1/用力肺活量(FVC)均明显高于对照组(P<0.05);观察组mMRC评分明显低于对照组(P<0.05);两组治疗期间不良反应发生率比较差异无统计学意义(P>0.05)。结论:舒利迭联合标准桃金娘油肠溶胶囊用于慢性阻塞性肺疾病效果显著,可有效调节血清SIRT1、sfrp5、MRpro-ADM的表达,缓解气道炎症反应,改善肺功能,临床应用价值高。
Objective: To investigate the efficacy of seretide combined with standard Myrtle oil enteric-coated capsule in the treatment of chronic obstructive pulmonary disease and its effects on serum SIRT1, Sfrp5 and MRpro-ADM. Methods: 100 patients of chronic obstructive pulmonary disease who received therapy from April 2016 to April 2018 in our hospital were selected as research objects, they were divided into observation group(55 cases) and control group(45 cases) by the simple random number table method, On the basis of routine treatment, the control group was treated with seretide while the observation group was treated with Standard Myrtle oil enteric-coated on the basis of the control group, they were treated for 8 weeks. The clinical efficacy, serum SIRT1, sfrp5, MRpro-ADM, lung function, respiratory questionnaire(mMRC) score and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than those in the control group(P<0.05); the serum SIRT1 and Sfrp5 levels in the observation group were significantly higher than those in the control group, and MRpro-ADM levels was significantly lower than those in the control group(P<0.05); the first second forced expiratory volume(FEV1) and FEV1/forced vital capacity(FVC) in the observation group were significantly higher than those in the control group(P<0.05); the mMRC score of the observation group was significantly lower than those in the control group(P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05). Conclusion: Seretide combined with standard Myrtle oil enteric-coated capsule has remarkable effect on chronic obstructive pulmonary disease. It can effectively regulate the expression of SIRT1, Sfrp5 and MRpro-ADM in serum, alleviate airway inflammation and improve lung function. It has high clinical value.
Objective: To investigate the efficacy of seretide combined with standard Myrtle oil enteric-coated capsule in the treatment of chronic obstructive pulmonary disease and its effects on serum SIRT1, Sfrp5 and MRpro-ADM. Methods: 100 patients of chronic obstructive pulmonary disease who received therapy from April 2016 to April 2018 in our hospital were selected as research objects, they were divided into observation group(55 cases) and control group(45 cases) by the simple random number table method, On the basis of routine treatment, the control group was treated with seretide while the observation group was treated with Standard Myrtle oil enteric-coated on the basis of the control group, they were treated for 8 weeks. The clinical efficacy, serum SIRT1, sfrp5, MRpro-ADM, lung function, respiratory questionnaire(mMRC) score and adverse reactions were compared between the two groups. Results: After treatment, the total effective rate of the observation group was significantly higher than those in the control group(P<0.05); the serum SIRT1 and Sfrp5 levels in the observation group were significantly higher than those in the control group, and MRpro-ADM levels was significantly lower than those in the control group(P<0.05); the first second forced expiratory volume(FEV1) and FEV1/forced vital capacity(FVC) in the observation group were significantly higher than those in the control group(P<0.05); the mMRC score of the observation group was significantly lower than those in the control group(P<0.05); there was no significant difference in the incidence of adverse reactions between the two groups during treatment(P>0.05). Conclusion: Seretide combined with standard Myrtle oil enteric-coated capsule has remarkable effect on chronic obstructive pulmonary disease. It can effectively regulate the expression of SIRT1, Sfrp5 and MRpro-ADM in serum, alleviate airway inflammation and improve lung function. It has high clinical value.
引文
[1] 祁玉诚,侯淑萍.慢性阻塞性肺疾病的流行病学调查及影响因素分析[J].中国现代药物应用,2017,11(4):77～79.
[2] Brzoska K,Barttomiejczyk T,Sochanowicz B,et al.Carcinogenesis-related changes in iron metabolism in chronic obstructive pulmonary disease subjects with lung cancer[J].Oncol Lett,2018,16(5):6831～6837.
[3] Li H,Chen LLJ,Liu LL,et al.Development of myrtol standardized for clinical application[J].China Pharmaceuticals,2012,21(15):1～3.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67～80.
[5] 郑成功,胡瑞成,戴爱国.Sirt1在呼吸系统疾病中的研究进展[J].临床与病理杂志,2017,37(4):825～830.
[6] Gu C,Li Y,Liu J,et al.LncRNA-mediated SIRT1/FoxO3a and SIRT1/p53 signaling pathways regulate type II alveolar epithelial cell senescence in patients with chronic obstructive pulmonary disease[J].Mol Med Rep,2017,15(5):3129～3134.
[7] Li GY,Yin SJ,Liu Y,et al.Correlation analysis of serum secreted frizzled-related protein 5 levels with airway inflammation and insulin resistance in chronic obstructive pulmonary disease patients[J].Chinese Journal of tuberculosis and Respiratory Medicine,2017,40(12):903～908
[8] Feng L,Xu FF.Observation on the efficacy of standard Myrtle oil enteric-coated capsule combined with vibration expectorator in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease[J].Shenzhen Journal of Integrated Traditional Chinese and Western Medicine February,2017,27(4):32～33.
[9] 冯莉,涂芳芳.标准桃金娘油肠溶胶囊联合振动排痰机治疗老年慢性阻塞性肺疾病急性加重期的疗效观察[J].深圳中西医结合杂志,2017,27(4):32～33.
[10] Zhang JB,Lu JH.Standard myrtle oil intestines dissolving capsule in treatment of children with acute bronchitis curative effects[J].Chin of Clinical Rational Drug Use,2012,5(3B):32～33.
[2] Brzoska K,Barttomiejczyk T,Sochanowicz B,et al.Carcinogenesis-related changes in iron metabolism in chronic obstructive pulmonary disease subjects with lung cancer[J].Oncol Lett,2018,16(5):6831～6837.
[3] Li H,Chen LLJ,Liu LL,et al.Development of myrtol standardized for clinical application[J].China Pharmaceuticals,2012,21(15):1～3.
[4] 中华医学会呼吸病学分会慢性阻塞性肺疾病学组.慢性阻塞性肺疾病诊治指南(2013年修订版)[J].中国医学前沿杂志(电子版),2014,6(2):67～80.
[5] 郑成功,胡瑞成,戴爱国.Sirt1在呼吸系统疾病中的研究进展[J].临床与病理杂志,2017,37(4):825～830.
[6] Gu C,Li Y,Liu J,et al.LncRNA-mediated SIRT1/FoxO3a and SIRT1/p53 signaling pathways regulate type II alveolar epithelial cell senescence in patients with chronic obstructive pulmonary disease[J].Mol Med Rep,2017,15(5):3129～3134.
[7] Li GY,Yin SJ,Liu Y,et al.Correlation analysis of serum secreted frizzled-related protein 5 levels with airway inflammation and insulin resistance in chronic obstructive pulmonary disease patients[J].Chinese Journal of tuberculosis and Respiratory Medicine,2017,40(12):903～908
[8] Feng L,Xu FF.Observation on the efficacy of standard Myrtle oil enteric-coated capsule combined with vibration expectorator in the treatment of elderly patients with acute exacerbation of chronic obstructive pulmonary disease[J].Shenzhen Journal of Integrated Traditional Chinese and Western Medicine February,2017,27(4):32～33.
[9] 冯莉,涂芳芳.标准桃金娘油肠溶胶囊联合振动排痰机治疗老年慢性阻塞性肺疾病急性加重期的疗效观察[J].深圳中西医结合杂志,2017,27(4):32～33.
[10] Zhang JB,Lu JH.Standard myrtle oil intestines dissolving capsule in treatment of children with acute bronchitis curative effects[J].Chin of Clinical Rational Drug Use,2012,5(3B):32～33.